A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).
  Medline CASGoogle Scholar
• 2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017).
  MedlineGoogle Scholar
• 3 Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609–615 (2011).
  MedlineGoogle Scholar
• 4 Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin. Cancer Res. 20(20), 5150–5156 (2014).
  Medline CASGoogle Scholar
• 5 Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract. Robboy SL, Mutter GL, Prat J (Eds). Churchill Livingstone Elsevier, Oxford, UK, 601 (2009).
  Google Scholar
• 6 Desai A, Xu J, Aysola K et al. Epithelial ovarian cancer: an overview. World J. Transl. Med. 3(1), 1–8 (2014).
  MedlineGoogle Scholar
• 7 Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 6(5), 229–239 (2014).
  Medline CASGoogle Scholar
• 8 Della Pepa C, Tonini G, Pisano C et al. Ovarian cancer standard of care: are there real alternatives? Chin. J. Cancer 34(1), 17–27 (2015).
  Medline CASGoogle Scholar
• 9 Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol. Oncol. 133(3), 624–631 (2014).
  Medline CASGoogle Scholar
• 10 Tapia G, Diaz-Padilla I. Molecular mechanisms of platinum resistance in ovarian cancer. In: Ovarian Cancer - A Clinical And Translational Update. Diaz-Padilla I (Ed.). InTech (2013).
  Google Scholar
• 11 Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 12(12), 1169–1174 (2011).
  Medline CASGoogle Scholar
• 12 Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int. J. Gynecol. Cancer 21(4), 750–755 (2011).
  MedlineGoogle Scholar
• 13 Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 5(1), 26–35 (2000).
  Medline CASGoogle Scholar
• 14 Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16(4), 1494–1497 (1998).
  Medline CASGoogle Scholar
• 15 Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 115(3), 377–381 (2009).
  Medline CASGoogle Scholar
• 16 Wagner U, Marth C, Largillier R et al. Final overall survival results of Phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 107(4), 588–591 (2012).
  Medline CASGoogle Scholar
• 17 Herzog TJ, Armstrong DK, Brady MF et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol. Oncol. 132, 8–17 (2014).
  MedlineGoogle Scholar
• 18 Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med. Oncol. 34(6), 103 (2017).
  MedlineGoogle Scholar
• 19 Bookman MA, Brady MF, Mcguire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the gynecologic cancer intergroup. J. Clin. Oncol. 27(9), 1419–1425 (2009).
  Medline CASGoogle Scholar
• 20 Du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24(7), 1127–1135 (2006).
  Medline CASGoogle Scholar
• 21 Lheureux S, Karakasis K, Kohn EC, Oza AM. Ovarian cancer treatment: the end of empiricism? Cancer 121(18), 3203–3211 (2015).
  MedlineGoogle Scholar
• 22 Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. Crit. Rev. Oncol. Hematol. 98, 180–188 (2016).
  MedlineGoogle Scholar
• 23 Symeonides S, Gourley C. Ovarian cancer molecular stratification and tumor heterogeneity: a necessity and a challenge. Front. Oncol. 5, 229 (2015).
  MedlineGoogle Scholar
• 24 Colombo N, Conte PF, Pignata S, Raspagliesi F, Scambia G. Bevacizumab in ovarian cancer: focus on clinical data and future perspectives. Crit. Rev. Oncol. Hematol. 97, 335–348 (2016).
  MedlineGoogle Scholar
• 25 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br. J. Cancer 115(10), 1157–1173 (2016).
  Medline CASGoogle Scholar
• 26 Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur. J. Cancer 47(Suppl. 3), S116–S130 (2011).
  Medline CASGoogle Scholar
• 27 Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J. Ovarian Res. 7, 57 (2014).
  MedlineGoogle Scholar
• 28 Yoshida H, Yabuno A, Fujiwara K. Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Des. Devel. Ther. 9, 2351–2358 (2015).
  Medline CASGoogle Scholar
• 29 Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J. Nutr. 130(2), 129–132 (2000).
  Medline CASGoogle Scholar
• 30 Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updat. 17(4–6), 89–95 (2014).
  MedlineGoogle Scholar
• 31 Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu. Rev. Nutr. 31, 177–201 (2011).
  Medline CASGoogle Scholar
• 32 Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol. Ther. 13(14), 1355–1373 (2012).
  Medline CASGoogle Scholar
• 33 Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56(8), 1067–1084 (2004).
  Medline CASGoogle Scholar
• 34 Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26(1), 141–152 (2007).
  Medline CASGoogle Scholar
• 35 Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol. 26(10), 2034–2043 (2015).
  Medline CASGoogle Scholar
• 36 Kalli KR, Oberg AL, Keeney GL et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108(3), 619–626 (2008).
  Medline CASGoogle Scholar
• 37 Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34(1), 41–52 (2015). • Summarizes the role of folate receptor in ovarian cancer, and provides a rationale for targeting this receptor in the development of new therapeutic agents.
  Medline CASGoogle Scholar
• 38 Markert S, Lassmann S, Gabriel B et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 28(6A), 3567–3572 (2008).
  MedlineGoogle Scholar
• 39 O'shannessy DJ, Somers EB, Smale R, Fu YS. Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type. Int. J. Gynecol. Pathol. 32(3), 258–268 (2013).
  MedlineGoogle Scholar
• 40 Chen YL, Chang MC, Huang CY et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol. Oncol. 6(3), 360–369 (2012).
  Medline CASGoogle Scholar
• 41 Toffoli G, Russo A, Gallo A et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer 79(2), 121–126 (1998).
  Medline CASGoogle Scholar
• 42 Marchetti C, Palaia I, Giorgini M et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco. Targets Ther. 7, 1223–1236 (2014).
  Medline CASGoogle Scholar
• 43 Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther. 10(3), 431–437 (2010).
  Medline CASGoogle Scholar
• 44 Gokhale M, Thakur A, Rinaldi F. Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev. Ind. Pharm. 39(9), 1315–1327 (2013).
  Medline CASGoogle Scholar
• 45 Ambrosio AJ, Suzin D, Palmer EL, Penson RT. Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer. Expert Rev. Clin. Pharmacol. 7(4), 443–450 (2014).
  Medline CASGoogle Scholar
• 46 Lutz RJ. Targeting the folate receptor for the treatment of ovarian cancer. Transl. Cancer Res. 4(1), 118–126 (2015).
  CASGoogle Scholar
• 47 Vergote I, Armstrong D, Scambia G et al. A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol. 34(19), 2271–2278 (2016).
  Medline CASGoogle Scholar
• 48 Merck and Endocyte announce independent DSMB recommends vintafolide proceed Phase III trial be stopped for futility following interim analysis (2014). http://investor.endocyte.com/releasedetail.cfm?releaseid=844838.
  Google Scholar
• 49 Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized Phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 31(35), 4400–4406 (2013).
  Medline CASGoogle Scholar
• 50 Kline JB, Kennedy RP, Albone E et al. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-gamma receptor engagement. Oncotarget 8(32), 52045–52060 (2017).
  MedlineGoogle Scholar
• 51 Chari RV, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53(15), 3796–3827 (2014).
  Medline CASGoogle Scholar
• 52 Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM. Antibody–drug conjugates for cancer therapy. Biomedicines 4(3), 14 (2016).
  Google Scholar
• 53 Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 17(6), e254–e262 (2016).
  Medline CASGoogle Scholar
• 54 Lambert JM, Morris CQ. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv. Ther. 34(5), 1015–1035 (2017). • Provides a comprehensive review of the current status of antibody–drug conjugates undergoing advanced clinical testing, with emphasis on solid tumors.
  Medline CASGoogle Scholar
• 55 Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 76(2), 248–262 (2013).
  Medline CASGoogle Scholar
• 56 Lutz RJ. Targeting the folate receptor for the treatment of ovarian cancer. Transl. Cancer Res. 4, 118–126 (2015).
  CASGoogle Scholar
• 57 Oroudjev E, Lopus M, Wilson L et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 9(10), 2700–2713 (2010).
  Medline CASGoogle Scholar
• 58 Goldmacher VS, Audette CA, Guan Y et al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS ONE 10(2), e0117523 (2015).
  MedlineGoogle Scholar
• 59 Ab O, Whiteman KR, Bartle LM et al. IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against fralpha-expressing tumors. Mol. Cancer Ther. 14(7), 1605–1613 (2015). • Preclinical development and characterization of mirvetuximab soravtansine.
  Medline CASGoogle Scholar
• 60 Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66(8), 4426–4433 (2006).
  Medline CASGoogle Scholar
• 61 Kovtun YV, Audette CA, Ye Y et al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6), 3214–3221 (2006).
  Medline CASGoogle Scholar
• 62 Drewinko B, Patchen M, Yang LY, Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 41(6), 2328–2333 (1981).
  Medline CASGoogle Scholar
• 63 Gunderson CC, Moore KN. Mirvetuximab soravtansine. FRα-targeting ADC, treatment of epithelial ovarian cancer. Drugs of the Future 41(9), 539–545 (2016).
  Google Scholar
• 64 Moore KN, Borghaei H, O'malley DM et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody–drug conjugate, in patients with solid tumors. Cancer 123(16), 3080–3087 (2017).
  Medline CASGoogle Scholar
• 65 Konner JA, Bell-Mcguinn KM, Sabbatini P et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a Phase I study. Clin. Cancer. Res. 16(21), 5288–5295 (2010).
  Medline CASGoogle Scholar
• 66 Sasaki Y, Miwa K, Yamashita K et al. A Phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors. Invest. New Drugs 33(2), 332–340 (2015).
  Medline CASGoogle Scholar
• 67 Gomez-Roca CA, Boni V, Moreno V et al. A Phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870). J. Clin. Oncol. 34(Suppl.), Abstract 2511 (2016).
  Google Scholar
• 68 Parslow AC, Parakh S, Lee F, Gan HK, Scott AM. Antibody–drug conjugates for cancer therapy. Biomedicines 4(3), 14 (2016).
  Google Scholar
• 69 Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31(10), 589–604 (2015).
  Medline CASGoogle Scholar
• 70 Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 27(4), 655–664 (2008).
  Medline CASGoogle Scholar
• 71 Despierre E, Lambrechts S, Leunen K et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol. Oncol. 130(1), 192–199 (2013).
  Medline CASGoogle Scholar
• 72 Rubinsak LA, Cohen C, Khanna N, Horowitz IR, Hanley KZ. Folate receptor alpha expression in platinum resistant/refractory ovarian carcinomas and primary endocervical adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. doi:10.1097/PAI.0000000000000476 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 73 Martin LP, Konner J, Moore KN et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a Phase I study of mirvetuximab soravtansine, a FRα-targeting antibody–drug conjugate (ADC), in relapsed epithelial ovarian cancer patients. Gynecol. Oncol. 145, 34 (2017).
  Google Scholar
• 74 Moore KN, Martin LP, O'malley DM et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Phase I expansion study. J. Clin. Oncol. 35(10), 1112–1118 (2017). •• Data from a Phase I expansion cohort study indicating that mirvetuximab soravtansine is clinically active in patients with platinum-resistant epithelial ovarian cancer.
  Medline CASGoogle Scholar
• 75 Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14), 3312–3322 (2001).
  Medline CASGoogle Scholar
• 76 Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26(6), 890–896 (2008).
  Medline CASGoogle Scholar
• 77 Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J. Clin. Oncol. 32(13), 1302–1308 (2014). •• Results of a pivotal Phase III trial that resulted in approval of bevacizumab for the treatment of ovarian cancer.
  Medline CASGoogle Scholar
• 78 Moore KN, Matulonis UA, O'malley DM et al. Mirvetuximab soravtansine (IMGN853), a folate alpha (FRα)-targeting antibody–drug conjugate (ADC), in platinum-resistant epithelial ovarian caner (EOC) patients (pts): Activity and safety analyses in Phase I pooled expansion cohorts. J. Clin. Oncol. 35(Suppl.), Abstract 5547 (2017).
  Google Scholar
• 79 Ponte JF, Ab O, Lanieri L et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody–drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18(12), 775–784 (2016). • Preclinical studies demonstrating combinatorial benefit conferred by the addition of mirvetuximab soravtansine to established therapeutic agents used in the treatment of epithelial ovarian cancer.
  Medline CASGoogle Scholar
• 80 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58–62 (2005).
  Medline CASGoogle Scholar
• 81 Arjaans M, Schroder CP, Oosting SF, Dafni U, Kleibeuker JE, De Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 7(16), 21247–21258 (2016).
  MedlineGoogle Scholar
• 82 O'malley DM, Moore KN, Vergote I et al. Safety findings from FORWARD II: a Phase Ib study evaluating the folate recepotr alpha (FRα)-targeting antibody–drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. J. Clin. Oncol. 35(Suppl.), Abstract 5553 (2017).
  MedlineGoogle Scholar
• 83 Ye H, Karim AA, Loh XJ. Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review. Mater. Sci. Eng. C Mater. Biol. Appl. 45, 609–619 (2014).
  Medline CASGoogle Scholar
• 84 Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015).
  MedlineGoogle Scholar
• 85 Weiss L, Huemer F, Mlineritsch B, Greil R. Immune checkpoint blockade in ovarian cancer. Memo 9, 82–84 (2016).
  MedlineGoogle Scholar
• 86 Mittica G, Genta S, Aglietta M, Valabrega G. Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int. J. Mol. Sci. 17(7), pii:E1169 (2016).
  MedlineGoogle Scholar
• 87 Varga A, Piha-Paul SA, Ott PA et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. J. Clin. Oncol. 35(15 Suppl.), 5513–5513 (2017).
  Google Scholar
• 88 Skaletskaya A, Ponte JF, Chittenden T, Setiady J. Treatment of tumor cells with mirvetuximab soravtansine, a FRα-targeting antibody–drug conjugate (ADC), activates monocytes through Fc-FcgR interaction and immunogenic cell death. J. ImmunoTher. Cancer 4(Suppl. 1), 73 (2016).
  Google Scholar
• 89 Muller P, Kreuzaler M, Khan T et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7(315), 315ra188 (2015).
  MedlineGoogle Scholar